


Is Low-Dose Alteplase a Better Treatment Option for Patients with Acute Lacunar Ischemic Stroke?


Intravenous thrombolysis using alteplase has been reported to provide favorable outcomes in patients with lacunar acute ischemic stroke (AIS)




Study question

Are there differences in safety and efficacy between low-dose and standard-dose alteplase in patients with lacunar AIS?

Post-hoc analysis of the ENCHANTED trial




Patients with lacunar AIS were less likely to be deceased or disabled at 90 days (aOR [95% CI]: 0.60 [0.47–0.77])



No difference of functional outcomes in all participants based on dose in adjusted analysis (aOR [95% CI]: 1.04 [0.87–1.24])



Reduced risk of ICH with low dose alteplase in lacunar AIS (ECASS-3 criteria 0.37) did not translate into improved functional outcome



Low-dose alteplase provided no advantage over standard dose alteplase in patients with lacunar AIS